List of Treatments for Lung Cancer

Alecensa (Alectinib)

Overview
Alecensa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an… read more

Alunbrig (Brigatinib)

Overview
Alunbrig is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with ALK-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alunbrig is…

Augtyro (Repotrectinib)

Overview
Augtyro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Augtyro is also referred to… read more

Avastin (Bevacizumab)

Overview
Avastin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic, non-squamous, non-small cell lung cancer, as well as other types of cancer. Avastin is usually… read more

Braftovi (Encorafenib)

Overview
Braftovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in…

Catheter Placement

Overview
Catheter placement is a procedure used to remove excess fluid surrounding the lungs. In some cases of lung cancer, fluid builds up in the area of the chest outside the lungs and underneath the chest wall. This… read more

Chemotherapy

Overview
Chemotherapy is the treatment of cancer with drugs. Chemotherapy drugs may be given intravenously or orally after surgery (adjuvant chemotherapy) or before surgery (neoadjuvant chemotherapy). The goal of… read more

Cyramza (Ramucirumab)

Overview
Cyramza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC). Cyramza is often prescribed with erlotinib or docetaxel, two… read more

Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)

Overview
Enhertu is approved by the U.S. Food and Drug Administration (FDA) for treating adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and…

Gavreto (Pralsetinib)

Overview
Gavreto is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer as… read more

Gemzar (Gemcitabine)

Overview
Gemzar is approved by the U.S. Food and Drug Administration (FDA) for use in combination with the chemotherapy drug cisplatin for the treatment of non-small cell lung cancer (NSCLC). Gemzar is also known by its…

Gilotrif (Afatinib)

Overview
Gilotrif is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC) with nonresistant epidermal growth factor receptor mutations as… read more

Imdelltra (Tarlatamab-Dlle)

Overview
Imdelltra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive stage small cell lung cancer (SCLC) — cancer that has spread — whose disease has progressed…

Imfinzi (Durvalumab)

Overview
Imfinzi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating extensive small-cell lung cancer and late-stage (locally advanced or metastatic) non-small cell lung… read more

Imjudo (Tremelimumab-Actl)

Overview
Imjudo is approved by the U.S. Food and Drug Administration (FDA) in combination with durvalumab and platinum-based chemotherapy for the treatment of adults with metastatic non-small cell lung cancer (NSCLC)…

Iressa (Gefitinib)

Overview
Iressa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic, non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions… read more

Keytruda (Pembrolizumab)

Overview
Keytruda is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic small cell lung cancer and various non-small cell lung cancers. Keytruda is also referred to by its… read more

Krazati (Adagrasib)

Overview
Krazati is a brand name for the drug Adagrasib, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in adults. Specifically, it is used as a…

Laser Therapy

Overview
Laser therapy for lung cancer involves the use of a strong, focused light to destroy a small tumor in the lining of an airway or to decrease the size of a tumor that is blocking an airway. It is typically used… read more

Libtayo (Cemiplimab-Rwlc)

Overview
Libtayo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in adults. A person must have no EGFR, ALK, or ROS1 genetic mutations, and their cancer…

Lobectomy

Overview
Lobectomy surgery, or removing a lobe from a lung, is a treatment for advanced non-small cell lung cancer. The left lung has two lobes and the right has three.

What does it involve?
The procedure is… read more

Lorbrena (Lorlatinib)

Overview
Lorbrena is approved by the U.S. Food and Drug Administration (FDA) for treating adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. The FDA requires an approved test to…

Lumakras (Sotorasib)

Overview
Lumakras is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least…

Mekinist (Trametinib)

Overview
Mekinist is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with a mutation of the BRAF V600E gene as detected by an FDA-approved test.… read more

Mektovi (Binemetinib)

Overview
Mektovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in…